scholarly article | Q13442814 |
P356 | DOI | 10.1093/RHEUMATOLOGY/KEW240 |
P698 | PubMed publication ID | 27330160 |
P50 | author | Juhani Knuuti | Q11867479 |
Jarna C. Hannukainen | Q43288538 | ||
Timo Möttönen | Q59169124 | ||
Anna Kirjavainen | Q64438310 | ||
Antti Saraste | Q96170801 | ||
Laura Pirilä | Q104135946 | ||
Matti Haavisto | Q114563906 | ||
Anne Roivainen | Q41091972 | ||
Kari K. Kalliokoski | Q43235405 | ||
P2093 | author name string | Jukka Kemppainen | |
Timo Yli-Kerttula | |||
P2860 | cites work | Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients? | Q45235877 |
(18)Fluorodeoxyglucose positron emission tomography imaging of atherosclerotic plaque inflammation is highly reproducible: implications for atherosclerosis therapy trials. | Q48904408 | ||
Performance of the new generation of whole-body PET/CT scanners: Discovery STE and Discovery VCT. | Q50949090 | ||
Muscle-specific glucose and free fatty acid uptake after sprint interval and moderate-intensity training in healthy middle-aged men. | Q51306531 | ||
2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative | Q56506042 | ||
Measurement of patient outcome in arthritis | Q56879288 | ||
The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritis | Q27860872 | ||
EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis | Q33505914 | ||
Optimizing 18F-FDG PET/CT imaging of vessel wall inflammation: the impact of 18F-FDG circulation time, injected dose, uptake parameters, and fasting blood glucose levels. | Q33624365 | ||
PET in vasculitis | Q33947065 | ||
Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumati | Q34662758 | ||
American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. | Q34782898 | ||
The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. | Q35135831 | ||
Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study | Q35605663 | ||
The advancing clinical impact of molecular imaging in CVD. | Q37423120 | ||
Role of FDG-PET and PET/CT in the diagnosis and management of vasculitis | Q37695932 | ||
Imaging atherosclerotic plaque inflammation by fluorodeoxyglucose with positron emission tomography: ready for prime time? | Q37761792 | ||
Epidemiology of rheumatoid arthritis: rheumatoid arthritis and mortality | Q37774304 | ||
Cardiovascular disease in rheumatoid arthritis: state of the art and future perspectives | Q37812524 | ||
Rheumatoid arthritis and cardiovascular disease | Q38149252 | ||
Cardiovascular risk in rheumatoid arthritis: how to lower the risk? | Q38152504 | ||
PET imaging of inflammation in atherosclerosis | Q38218902 | ||
Relation of carotid artery 18F-FDG uptake to C-reactive protein and Framingham risk score in a large cohort of asymptomatic adults | Q38445305 | ||
An evaluation of risk factors for major adverse cardiovascular events during tocilizumab therapy | Q39110166 | ||
Measurement of arterial activity on routine FDG PET/CT images improves prediction of risk of future CV events | Q39309074 | ||
18F-FDG PET/CT identifies patients at risk for future vascular events in an otherwise asymptomatic cohort with neoplastic disease | Q39946694 | ||
Atherosclerosis inflammation imaging with 18F-FDG PET: carotid, iliac, and femoral uptake reproducibility, quantification methods, and recommendations | Q40091380 | ||
Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group | Q41924053 | ||
Subclinical vasculitis as a potential mechanism to explain the heightened cardiovascular risk in rheumatoid arthritis | Q42701584 | ||
P433 | issue | 10 | |
P304 | page(s) | 1777-1785 | |
P577 | publication date | 2016-06-21 | |
P1433 | published in | Rheumatology | Q7320492 |
P1476 | title | Influence of triple disease modifying anti-rheumatic drug therapy on carotid artery inflammation in drug-naive patients with recent onset of rheumatoid arthritis. | |
P478 | volume | 55 |
Q54202996 | Clinical Nononcologic Applications of PET/CT and PET/MRI in Musculoskeletal, Orthopedic, and Rheumatologic Imaging. |
Q33678290 | Imaging atherosclerosis in rheumatoid arthritis: evidence for increased prevalence, altered phenotype and a link between systemic and localised plaque inflammation. |
Search more.